Queen's University, Belfast
Belfast, Northern Ireland, BT12 6BJ, United Kingdom
NCT Number: NCT01889810
Insulin resistance is a state where the body does not respond as it should to the insulin it produces. Individuals who are insulin resistant are at increased risk of both heart disease and type 2 diabetes; importantly, diabetes more than doubles the risk of heart disease, independent of other recognised risk factors. Interventions that prevent or reverse insulin resistance may help to attenuate risk of heart disease and diabetes. A number of randomised controlled trials provide proof of concept evidence regarding a beneficial effect of vitamin D on insulin resistance and other cardiovascular risk markers but experts have stated that further studies are required. Importantly, these studies should use appropriate endpoints, provide a high enough dose of vitamin D to optimise vitamin D status, and they should be conducted in clearly defined populations, The vitamin D trial we propose addresses these issues and aims to evaluate a potentially straightforward and low cost health care intervention for populations at highrisk of heart disease and diabetes. Specifically, this study would provide clinically relevant information on the metabolic effects of optimising vitamin D status in these high risk patients. This has clear economic and social implications given the current, and projected, burden of heart disease and diabetes.
This study will investigate the effect of vitamin D3 supplementation on insulin resistance and cardiovascular risk factors in people at high risk of type 2 diabetes and cardiovascular disease using the gold standard euglycaemic hyperinsulinaemic clamp method.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Belfast, Northern Ireland, BT12 6BJ, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
Time frame: Measured at baseline and after 6 months
Insulin resistance will be measured using the gold standard euglycaemic-hyperinsulinaemic clamp method (note - it is anticipated that a total of 60 volunteers will complete the primary endpoint assessment).
Time frame: Measured at baseline and after 6 months
Change in vitamin D status will be measured using the gold standard Ultra performance liquid chromatography followed by tandem mass spectrometry
Time frame: Measured at baseline and after 6 months
Measurements of seated and 24-hour ambulatory blood pressure, lipids, homeostasis model assessment (HOMA), HbA1c, and inflammatory and immune function markers including tumour necrosis factor-alpha and high sensitivity c-reactive protein
Time frame: Measured at baseline and after 6 months
Assessed by sequential tonometry with ECG gating using the SphygmoCor PWV System
Time frame: Measured at baseline and after 6 months
Assessed using hand held dynamometer
Time frame: Measured at baseline and after 6 months
SF-36 Questionnaire
Queen's University, Belfast
Other
Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in People at High Risk of Type 2 Diabetes and Cardiovascular Disease (The DIR Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01476501
Bone Disease, Bone Diseases
Edmonton, Alberta, Canada
View Trial DetailsNCT02179788
Behavior, Breast Feeding
Cincinnati, Ohio, United States
View Trial DetailsNCT00536250
Body Weight, Childhood Obesity
New Haven, Connecticut, United States
View Trial DetailsNCT00402194
Body Weight, Glucose Intolerance
Indianapolis, Indiana, United States
View Trial Details